Infinity Pharmaceuticals (INFIQ) 10-K2018 FY Annual report

Filed: 14 Mar 19, 7:06am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: abdominal, accident, accidental, activitiesproduct, adenosine, adolescent, Agresta, Albino, antagonist, argued, attorney, bevacizumab, billion, bladder, blueprint, boost, Boston, causebreach, Circuit, clause, CMC, Combo, compassionate, constraint, context, corridor, customer, dashboard, dehydrogenase, denied, depth, donut, elaborated, elevated, enasidineb, eudract, excessive, exploratory, extinguish, extinguishing, faculty, falsification, fellowship, Florida, fluid, fraction, furlough, gag, gallbladder, gaming, GDPR, GlaxoSmithKline, Gliobastoma, glioblastoma, harbor, HCR, HHS, hole, homeostatic, intraperitoneally, isocitrate, ivosidenib, judge, leakage, Lee, left, ligand, liver, lodge, MA, master, McGovern, membership, men, Merrimack, microsatellite, Moffitt, movement, murine, myeloid, Nonemployee, operationalize, oversaw, pain, penetrate, percent, perception, PRA, PREA, precedent, predominantly, predominate, prespecified, problem, proliferative, RCC, regression, regrowth, relaxing, renal, reprogram, Reprogramming, restraining, Samuel, sarcoma, sentence, shorter, sophisticated, South, speed, stream, supervisory, synergistic, TCJA, temozolomide, TheFor, therewith, TMZ, tropical, Tulane, unaffected, uncomplicated, unfairly, urothelial, Vaccinex, virtually, withheld

Removed: bank, BHX, broker, cancellable, collateralize, commencing, construction, contemplated, custodial, damaging, deliverable, deposit, deposited, discussed, DYNAMO, DYNAMOTM, endorse, equally, fall, FDASIA, forecast, forfeiture, graph, hypothetical, index, indolent, iNHL, installment, involvement, irrevocable, mark, nationally, North, occupancy, originally, override, passed, perpetual, proportional, proportionate, rated, Realty, receivable, regained, reinvested, rendered, retail, separated, shared, speculative, standby, structural, sued, Trust, trustee, unaudited

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated INFIQ transcripts

INFIQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

STATEMENT PURSUANT TO 18 U.S.C. §1350

Pursuant to 18 U.S.C. §1350, the undersigned certifies that, to his knowledge, this Annual Report on Form 10-K for the period ended December 31, 2018 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Infinity Pharmaceuticals, Inc.




Date: March 14, 2019			/s/ Lawrence E. Bloch, M.D., J.D.
			Lawrence E. Bloch, M.D., J.D.
			President
			(Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to Infinity Pharmaceuticals, Inc. and will be retained by Infinity Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.